Sign In
Buy LFMD
$3.50
-0.140 (-3.85%)
At Close: Jul 31, 2026
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
09:48am, Thursday, 02'nd Oct 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options If you suffered losses in Lif
LifeMD, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LFMD
08:31am, Thursday, 02'nd Oct 2025
LOS ANGELES , Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD " or "the Company") (NASDAQ: LFMD ) for violations of §§10(b) a
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm
08:29am, Thursday, 02'nd Oct 2025
LOS ANGELES , Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD" or "the Co
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
SAN DIEGO , Oct. 1, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired LifeMD, Inc. (NASDAQ: LF
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
05:09pm, Wednesday, 01'st Oct 2025
NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025,
Shareholders of LifeMD, Inc. Should Contact Levi & Korsinsky Before October 25, 2025 to Discuss Your Rights – LFMD
04:25pm, Wednesday, 01'st Oct 2025
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit.
LifeMD (LFMD) Faces Lawsuit Over Alleged Concealment of Cost and Refund Woes in Key Segments, According to Hagens Berman
02:32pm, Wednesday, 01'st Oct 2025
Investors who lost money in LifeMD after its stock plunged 44 percent due to allegedly misleading financial statements are urged to contact Hagens Berman.
LifeMD, Inc. (LFMD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Wednesday, 01'st Oct 2025
LOS ANGELES , Oct. 1, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against LifeMD, Inc. ("Li
LFMD LAWSUIT ALERT: Levi & Korsinsky Notifies LifeMD, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
08:45am, Wednesday, 01'st Oct 2025
NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit. CLASS DEFINITIO
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5,
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
10:30am, Tuesday, 30'th Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options
LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers
08:14am, Tuesday, 30'th Sep 2025
Telehealth firm LifeMD said on Tuesday it would collaborate with Novo Nordisk to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients, including those who are insured and whose
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
08:00am, Tuesday, 30'th Sep 2025
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk
LifeMD allegedly overstated its competitive position and raised guidance despite rising acquisition costs, rendering its statements misleading to investors
